Stemtech (STEK) Depreciation & Amortization (CF) (2021 - 2025)
Stemtech's (STEK) quarterly Depreciation & Amortization (CF) came in at $41865.0 in Q4 2025, down 77.37% year-on-year from $184997.0 in Q4 2024, and little changed quarter-over-quarter from $41877.0 in Q3 2025.
Stemtech (STEK) Depreciation & Amortization (CF) (2021 - 2025) Analysis & Trends
Stemtech has disclosed Depreciation & Amortization (CF) across 5 years of filings, most recently posting $41865.0 for Q4 2025.
- Depreciation & Amortization (CF) for Q4 2025 came in at $41865.0, down 77.37% year-over-year; the trailing twelve-month figure through Dec 2025 was $167495.0 (down 51.38% YoY), and the FY2025 annual result was $167495.0, down 51.38% from the prior year.
- Depreciation & Amortization (CF) came in at $41865.0 for Q4 2025 at Stemtech, roughly flat from $41877.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $426307.0 in Q1 2021 to a low of -$202321.0 in Q2 2021.
- The 5-year median for Depreciation & Amortization (CF) is $109597.0 (2022), against an average of $103985.8.
- Across the five-year window, Depreciation & Amortization (CF) slumped 96.53% in 2024 and jumped 685.1% in 2025, its largest moves.
- Stemtech's Depreciation & Amortization (CF) stood at $103478.0 in 2021, then gained by 13.28% to $117217.0 in 2022, then jumped by 32.87% to $155748.0 in 2023, then rose by 18.78% to $184997.0 in 2024, then slumped by 77.37% to $41865.0 in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $41865.0 (Q4 2025), $41877.0 (Q3 2025), and $41877.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Stemtech | - | - | 354,677.00 | 41,865.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 41,865.00 |
| Dec 31, 2025 | 41,865.00 |
| Sep 30, 2025 | 41,877.00 |
| Sep 30, 2025 | 41,877.00 |
| Jun 30, 2025 | 41,877.00 |
| Jun 30, 2025 | 41,877.00 |
| Mar 31, 2025 | 41,876.00 |
| Mar 31, 2025 | 41,876.00 |
| Dec 31, 2024 | 184,997.00 |
| Dec 31, 2024 | 184,997.00 |
| Jun 30, 2024 | 5,334.00 |
| Jun 30, 2024 | 5,334.00 |
| Mar 31, 2024 | 154,135.00 |
| Mar 31, 2024 | 154,135.00 |
| Dec 31, 2023 | 155,748.00 |
| Dec 31, 2023 | 155,748.00 |
| Sep 30, 2023 | 158,556.00 |
| Sep 30, 2023 | 158,556.00 |
| Jun 30, 2023 | 153,895.00 |
| Jun 30, 2023 | 153,895.00 |